Renjing Biology
RinuaGene Biotechnology Co., Ltd., established in 2021, is a biopharmaceutical company focused on innovative mRNA therapeutics and vaccines. The company develops preventive vaccines for infectious diseases, virus-related therapeutic vaccines, tumor immunotherapies, and protein replacement therapies. RinuaGene has a strong technological platform optimizing linear and circular mRNA design, targeted delivery, CMC, data science, and AI for RNA. It holds a comprehensive international patent portfolio with 74 invention patents and 3 software copyrights. RinuaGene's lead product, the mRNA therapeutic vaccine RG002 for HPV-related tumors and precancerous lesions, received FDA IND approval in 2023, marking it as the world's first approved mRNA-LNP therapeutic vaccine for HPV 16/18-related cervical intraepithelial neoplasia. The company is recognized as a "Potential Unicorn" and "Unicorn Cultivation" enterprise in Jiangsu, China, reflecting its innovation strength and growth potential. RinuaGene employs a highly educated R&D team and aims to build international competitiveness in RNA therapeutics and vaccines.
Renjing Biology
RinuaGene Biotechnology Co., Ltd., established in 2021, is a biopharmaceutical company focused on innovative mRNA therapeutics and vaccines. The company develops preventive vaccines for infectious diseases, virus-related therapeutic vaccines, tumor immunotherapies, and protein replacement therapies. RinuaGene has a strong technological platform optimizing linear and circular mRNA design, targeted delivery, CMC, data science, and AI for RNA. It holds a comprehensive international patent portfolio with 74 invention patents and 3 software copyrights. RinuaGene's lead product, the mRNA therapeutic vaccine RG002 for HPV-related tumors and precancerous lesions, received FDA IND approval in 2023, marking it as the world's first approved mRNA-LNP therapeutic vaccine for HPV 16/18-related cervical intraepithelial neoplasia. The company is recognized as a "Potential Unicorn" and "Unicorn Cultivation" enterprise in Jiangsu, China, reflecting its innovation strength and growth potential. RinuaGene employs a highly educated R&D team and aims to build international competitiveness in RNA therapeutics and vaccines.